---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333827"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-08-05T11:08:16+00:00"
generated_at: "2026-08-05T11:10:07.506314+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam reports Q2 net loss of $64.1M; CHMP recommends EU approval for obicetrapib

## Summary
- CHMP positive opinion for obicetrapib monotherapy and FDC with ezetimibe; EC decision expected later 2026.
- Cash, cash equivalents and marketable securities $678.3M at June 30, 2026, down from $728.9M at Dec 31, 2025.
- Net loss $64.1M in Q2 2026 vs $17.4M in Q2 2025; revenue $3.7M vs $19.1M (prior year included $16.1M Menarini milestone).
- PREVAIL CVOT interim analysis planned for 4Q2026, result in 1Q2027; RUBENS Phase 3 topline data expected by year-end 2026.
- R&D expenses $41.7M (up from $27.5M) driven by clinical trial progression; SG&A $26.9M (down from $27.3M).

## SEC filing metadata
- accession: 0001193125-26-333827
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-08-05T11:08:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/0001193125-26-333827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333827
- JSON: https://secwatch.observer/filing/0001193125-26-333827.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.